Sign inJoin waitlistJoin the waitlist

PD

Paul DiSilvestro

Division Director, Gynecologic Oncology · Women and Infants Hospital of Rhode Island

Credentials: · · · · · ·

History

Gynecologic Oncology · Women and Infants Hospital of Rhode Island
Present

post-graduate training in gynecologic oncology at Women & Infants Hospital/Brown University
2001–2004
Gynecologic Oncology
University of Oklahoma-Health Sciences Center
1998–2001
Obstetrics and Gynecology
1994–1998
Robert Larner College of Medicine
1986–1990

Research

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
New England Journal of Medicine · 2018 · Last of 21 authors · 2,290 citations
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
New England Journal of Medicine · 2019 · 726 citations
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
Gynecologic Oncology · 2009 · 656 citations

Joan Walker
19 papers
Richard Moore
18 papers
Robert Mannel
18 papers
Kathleen Moore
17 papers
Matthew Powell
16 papers
CA
Carol Aghajanian
15 papers
CG
Cornelius Granai
15 papers
Krishnansu Tewari
15 papers
CM
Cara Mathews
14 papers · 2 as a resident
Michael Pearl
13 papers
David Mutch
12 papers
Bradley Monk
11 papers

Clinical trials

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Principal investigator · Active not recruiting · Phase 3
AstraZeneca
2013–2028
Doxil and Gemcitabine in Recurrent Ovarian Cancer
Principal investigator · Terminated · Phase 2
Women and Infants Hospital of Rhode Island
2006
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
Principal investigator · Terminated · Phase 3
National Cancer Institute (NCI)
2006–2010
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028